Gene changes found when a brain tumor stopped responding to vorasidenib
Original title: Emergence of inactivating NOTCH1 mutations in an IDH-mutant astrocytoma with clinical resistance to vorasidenib treatment.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This is one report about a person on treatment, not a new treatment.
The short version
Doctors found new gene changes in a tumor that stopped responding to a drug.
What was studied. This report describes a single person's astrocytoma, a kind of brain tumor. The tumor had an IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary and was treated with a drug called vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary. No abstract was available, so the details are very limited.
What they found. The report says the tumor stopped responding to vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary. Changes that switch off a gene called NOTCH1 showed up in the tumor. Because no abstract was available, no numbers or other results can be shared here.
What this means, and what it doesn't
What it could mean: Drugs like vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary can stop working over time in some people. This report points to one possible reason why that may happen. Clues like this may help doctors learn what to watch for.
What it doesn't mean: This is a single report, not a study in a group of people. It does not mean vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary stops working for everyone. It is not a new treatment, and it is not a cure. Nothing here changes the care a doctor can offer today.
Source: PubMed, October 15, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.